| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/18/1999 | WO1999007340A1 Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
| 02/18/1999 | WO1999007324A2 Conjugates targeted to the interleukin-2 receptor |
| 02/18/1999 | WO1999007224A1 Compositions and methods for treating diabetes |
| 02/18/1999 | WO1998051348A3 Sustained-release delayed gels |
| 02/18/1999 | WO1998049290A3 Syndecan interacting proteins and the use thereof |
| 02/18/1999 | WO1998049190A3 Substituted oxadiazole cysteine protease inhibitors |
| 02/18/1999 | WO1998046757A3 Secreted proteins and polynucleotides encoding them |
| 02/18/1999 | WO1998042833A3 Kv potassium channel polypeptides and polynucleotides |
| 02/18/1999 | WO1998040055A3 Anti-epileptogenic agents |
| 02/18/1999 | WO1998036764A3 Method of treating psychological and metabolic disorders using igf or igf/igfbp-3 |
| 02/18/1999 | WO1998033491A3 Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase |
| 02/18/1999 | WO1998014593A3 Human telomerase catalytic subunit |
| 02/18/1999 | DE19733651A1 Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole Aqueous aerosol formulations containing biologically active molecules Marko and method for generating appropriate aerosols |
| 02/18/1999 | CA2301669A1 Peptides having potassium channel opener activity |
| 02/18/1999 | CA2300977A1 Neutral sphingomyelinase |
| 02/18/1999 | CA2300921A1 Protein having pdz domain sequence |
| 02/18/1999 | CA2300478A1 Selective factor xa inhibitors |
| 02/18/1999 | CA2299617A1 1-a-alpha-hydroxylase materials and methods |
| 02/18/1999 | CA2299612A1 Selective factor xa inhibitors containing a fused azepinone structure |
| 02/18/1999 | CA2299610A1 Selective factor xa inhibitors |
| 02/18/1999 | CA2299554A1 Product comprising at least a double stranded rna combined with at least an antiviral agent |
| 02/18/1999 | CA2299467A1 Method to prevent accelerated atherosclerosis using (srage) soluble receptor for advanced glycation endproducts |
| 02/18/1999 | CA2299425A1 Novel exendin agonist compounds |
| 02/18/1999 | CA2299411A1 Heparin-binding growth factor (hbgf) polypeptides |
| 02/18/1999 | CA2299368A1 Conjugates targeted to the interleukin-2 receptor |
| 02/18/1999 | CA2299226A1 Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides |
| 02/18/1999 | CA2298932A1 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances |
| 02/18/1999 | CA2298849A1 Lipoprotein-regulating medicaments |
| 02/18/1999 | CA2298451A1 Secreted proteins and polynucleotides encoding them |
| 02/18/1999 | CA2298439A1 Lipocalin homologs |
| 02/18/1999 | CA2297945A1 Pharmaceutical composition with neurotrophic-like biological activity |
| 02/18/1999 | CA2297736A1 Treatment of acute lung injury and fibrosis with antagonists of .alpha.v.beta.6 |
| 02/18/1999 | CA2297174A1 Aqueous aerosol preparations containing biologically active macromolecules and process for producing the corresponding aerosols |
| 02/18/1999 | CA2296598A1 Isolation of a novel senescence-factor gene, p23 |
| 02/18/1999 | CA2294049A1 Hepatitis c inhibitor peptides |
| 02/18/1999 | CA2274302A1 Lsr receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications |
| 02/18/1999 | CA2267066A1 Meningococcus vaccine comprising the valence of bz83 strain |
| 02/17/1999 | EP0897011A2 Novel arginine deiminase |
| 02/17/1999 | EP0897009A2 HKABY60 polypeptides |
| 02/17/1999 | EP0897008A2 His5 |
| 02/17/1999 | EP0897007A2 MraY transferase |
| 02/17/1999 | EP0897004A2 Histidyl tRNA synthetase from Streptococcus pneumoniae (hisS) |
| 02/17/1999 | EP0897002A2 U62317, a protein having a JNK-binding domain |
| 02/17/1999 | EP0897001A1 Polypeptide having a GTPase regulator activity, nucleic acids coding therefore and their use in diagnostics and therapy |
| 02/17/1999 | EP0896965A1 Inhibitors of G-protein-beta, gamma subumit function |
| 02/17/1999 | EP0896626A1 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
| 02/17/1999 | EP0896625A2 Recombinant ribonuclease proteins |
| 02/17/1999 | EP0896622A1 Chemokine alpha 2 |
| 02/17/1999 | EP0896621A2 Cftr gene regulator |
| 02/17/1999 | EP0896620A1 Modified nuclear glucocorticoid receptor, fusion protein, and dna fragments coding for said receptor and said fusion protein |
| 02/17/1999 | EP0896615A1 Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
| 02/17/1999 | EP0896614A1 Human endometrial specific steroid-binding factor i, ii and iii |
| 02/17/1999 | EP0896586A1 ErbB3 ANTIBODIES |
| 02/17/1999 | EP0896585A1 Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation |
| 02/17/1999 | EP0896584A2 BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT HF-COLL-18/514cf) FOR INHIBITING THE GROWTH OF TUMOURS AND CAPILLARY PROFILERATIONS |
| 02/17/1999 | EP0896582A1 Non-dendritic backbone peptide carrier |
| 02/17/1999 | EP0896581A1 Treatment of preeclampsia, eclampsia or preterm labor with calcitonin gene related peptide and related drugs |
| 02/17/1999 | EP0896580A1 Specific immunophilin ligands as antiasthmatics and immunosuppressants |
| 02/17/1999 | EP0896545A1 Drug containing hcv hyperimmune globulins |
| 02/17/1999 | EP0896544A1 Combination of a somatostatin analogue and a rapamycin |
| 02/17/1999 | EP0896543A1 Drug for the treatment of tumours |
| 02/17/1999 | EP0896542A1 Method of restoring a functional protein in a tissue by cell transplantation |
| 02/17/1999 | EP0896538A1 Use of dipeptidyl peptidase iv inhibitors for lowering the blood glucose level in mammals |
| 02/17/1999 | EP0896525A1 Methods of dry powder inhalation |
| 02/17/1999 | EP0896516A1 Diabetic supplement bar |
| 02/17/1999 | EP0896506A1 Methods for inducing immune responsiveness in a subject |
| 02/17/1999 | EP0728016B1 Use of anti-idiotypic antibodies to prevent hyperacute rejection of xenografts |
| 02/17/1999 | EP0670711B1 Antifungal mouthcare compositions |
| 02/17/1999 | CN1208436A Novel polypeptide originating in hemophilus paragallinarum and process for producing the same |
| 02/17/1999 | CN1208420A Antisecretory factor peptides regulating pathological permeability changes |
| 02/17/1999 | CN1208405A Retroviral protease inhibiting compounds |
| 02/16/1999 | US5872299 Method of preparing intermediates for retroviral protease inhibitors |
| 02/16/1999 | US5872298 Method of preparing intermediates for retroviral protease inhibitors |
| 02/16/1999 | US5872251 Process for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof |
| 02/16/1999 | US5872242 Antisense oligonucleotide inhibition of ras |
| 02/16/1999 | US5872241 Multiple component RNA catalysts and uses thereof |
| 02/16/1999 | US5872237 Isolated nucleic acid sequences of dna or cdna for gene expression and dna sequences |
| 02/16/1999 | US5872235 Nucleic acids encoding tumor marker |
| 02/16/1999 | US5872234 Antitumor |
| 02/16/1999 | US5872233 Mycoplasma arthritidis T-cell mitogen |
| 02/16/1999 | US5872232 2'-O-modified oligonucleotides |
| 02/16/1999 | US5872231 Nucleic acids encoding merosin |
| 02/16/1999 | US5872230 Regulation of transport of cholesterol into the mitochondria of a cell for the synthesis of androgens, estrogens, glucocorticoids, mineralocorticoids, and progestagens. the invention also relates to methods for detecting and treating |
| 02/16/1999 | US5872227 Aggregation of cell membranes by lowering ph and separation of components |
| 02/16/1999 | US5872226 Fibroblast growth factor homologous factor-1 (FHF-1) |
| 02/16/1999 | US5872223 Immunoconjugates comprising tyrosine kinase inhibitors |
| 02/16/1999 | US5872222 Conjugate comprises nonimmunogenic polymer coupled with a plurality of binding molecules, each being specific for an antigen on a t cell, and binding molecule lacking an fc portion |
| 02/16/1999 | US5872220 Antibodies to insulin-like growth factor binding protein IGFBP-6 |
| 02/16/1999 | US5872219 Antibodies drawn to the eps15 substrate for epidermal growth factor receptor kinase |
| 02/16/1999 | US5872218 Monoclonal antibodies |
| 02/16/1999 | US5872214 NF2 isoforms |
| 02/16/1999 | US5872213 Purified protein, designated ini-1, capable of interacting with the hiv-1 integrase |
| 02/16/1999 | US5872210 Used in the treatment of virally infected cells, in the preparation of vaccine formulations, in the generation of clinically relevant antibodies and anti-idiotypic antibodies and in the generation of a screening assay or kit that can be |
| 02/16/1999 | US5872206 Polypeptides with amino acid sequences for screening |
| 02/16/1999 | US5872154 Method of reducing an immune response to a recombinant adenovirus |
| 02/16/1999 | US5872152 Use of MMP inhibitors |
| 02/16/1999 | US5872146 Metalloproteinases involved in connective tissue breakdown, such as collagenase, stromelysin and gelatinase and tumor necrosis factor |
| 02/16/1999 | US5872135 Enzyme inhibitors |
| 02/16/1999 | US5872133 Method of regulating the immune response |
| 02/16/1999 | US5872127 Method of regulating immune function |